Compare Amphastar Pharmaceuticals Inc (AMPH) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs MGM Resorts International — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while MGM Resorts International trades at $43.5 (market cap $10.91B). The key difference: MGM Resorts International is far larger — about 12.6× Amphastar Pharmaceuticals Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MGM | |
|---|---|---|
Market Cap | $863.95M | $10.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $50.69 |
52-Week Low | $16.87 | $30.72 |
Enterprise Value | $1.26B | $38.21B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
MGM Resorts International (MGM) trades at $44.47, down 0.51% on the day, with a bearish technical signal and neutral oscillators. The company reported record Q2 2026 revenue but missed earnings estimates, with net income margin at 2.4% and ROE at 15.44%. Recent news includes a potential acquisition investigation and BetMGM's expansion in Canada, while cash flow trends show improving net cash flow projections for 2026.
Outlook is mixed: analyst consensus leans neutral with a $51.14 price target, but risks include regulatory scrutiny and competitive pressures. The stock offers value with a P/S of 0.66, but investors should weigh earnings volatility and debt levels against growth in digital and Las Vegas operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
